Agonist and antagonist are the two words that appear in almost every compound description, and most explanations stop at "one turns the receptor on, the other blocks it". That is true and it is not enough, because a compound can bind a receptor tightly and still do nothing, and two compounds can both be agonists while producing different outcomes at the same receptor.
Binding and doing are separate properties
The lock-and-key picture hides the most useful idea in receptor pharmacology: a molecule's ability to attach to a receptor and its ability to produce a response are two independent things.
The first is affinity, which describes how readily the compound occupies the site. The second is efficacy, which describes what happens once it is there. The distinction was formalised in the 1950s and it is the reason the classification exists at all: agonists and antagonists can have identical affinity and differ entirely in efficacy. (Reference: Stephenson, 1956)
Agonists come in degrees
An agonist binds and activates. But activation is not all-or-nothing.
- A full agonist produces the maximum response the system can give.
- A partial agonist produces a submaximal response even when every receptor is occupied. Adding more does not close the gap, because the ceiling belongs to the compound and not to the dose.
A partial agonist in the presence of a full one therefore behaves partly like a blocker, since it occupies sites that would otherwise give a full response. The categories are not as clean as the vocabulary suggests.
Antagonists block, in more than one way
An antagonist occupies the receptor without activating it. How it blocks matters.
- Competitive antagonists compete for the same site. Enough agonist will outcompete them, so the block can be overcome.
- Non-competitive and allosteric antagonists act elsewhere on the receptor, changing its behaviour without contesting the binding site. Adding more agonist does not restore the full response.
In the laboratory the difference shows up as a shift in the concentration-response curve for the first case and a reduction of its maximum for the second.
Receptors can be active with nothing bound
The classical picture assumes a receptor sits silent until something arrives. Many do not. A fraction of receptors adopts the active conformation spontaneously, producing what is called constitutive activity, and a compound can bind and reduce that baseline below where it would sit with nothing present at all. That compound is an inverse agonist, a third category that the on-or-off framing has no room for. (Reference: Milligan, 2003)
The practical consequence is historical as much as technical. Compounds catalogued as neutral antagonists before constitutive activity was widely recognised were later re-examined, and a number of them turned out to be inverse agonists. The classification depends on what the assay was able to see.
Two agonists at one receptor are not necessarily equivalent
A receptor usually has more than one downstream route available. A compound can engage a receptor and favour one of those routes over another, so two agonists at the same target can produce different patterns of activity instead of more or less of the same thing. This is called biased agonism or functional selectivity. (Reference: Kenakin, 2011)
It is not an exotic edge case. Tirzepatide has been characterised in exactly those terms: it engages two receptors, and it engages them unevenly. Calling it a dual agonist is accurate and tells you nothing about the balance.
Where selectivity fits
Few receptors exist alone. Most belong to families whose members share enough structure that a compound shaped for one will often touch its relatives, and selectivity is the word for how cleanly it avoids doing so. It is a comparison, never an absolute: a compound is selective for one subtype over another by some factor, under some conditions.
Ipamorelin is described as selective for that reason, and the recurring question for any melanocortin agonist such as PT-141 is which of the receptor subtypes it engages and how strongly. For a research tool, selectivity is what makes an observation attributable: the cleaner the profile, the fewer alternative explanations for what was measured.
The label is partly a property of the experiment
Most explanations leave this out. Whether a compound looks like a full agonist or a partial one depends on the compound and on the system it is measured in: how many receptors are present, how strongly the readout amplifies the signal, and which downstream event is being observed. Frameworks exist precisely to separate what belongs to the molecule from what belongs to the assay. (Reference: Black & Leff, 1983) (Reference: Kenakin, 2004)
The practical reading: a compound described as an agonist in one paper and a partial agonist in another may not be a contradiction. It may be two systems.
What the word tells you about a vial, and what it does not
Almost every compound in this catalogue is described as a receptor agonist. Ipamorelin at the ghrelin receptor, PT-141 at melanocortin receptors, tirzepatide at the incretin receptors. The term describes what the molecule is understood to do at its target, drawn from published work.
It does not describe the material in front of you. "Agonist" is a statement about a structure; it says nothing about whether this batch contains that structure, how pure it is, or whether the right molecule is in the vial. Those questions are answered by a certificate of analysis and by checking a batch number, not by a word in a description.
Research use only
This article is background pharmacology for laboratory context. All products sold by Codex Research are strictly for research and development, are not for human or animal consumption, and are not intended to diagnose, treat, cure, or prevent any disease.
These compounds in the catalog
Frequently asked questions
What is the difference between an agonist and an antagonist?
An agonist binds a receptor and activates it. An antagonist binds but does not activate, occupying the site so an agonist cannot act there. The distinction is about efficacy, not about how well the compound binds.
What is the difference between affinity and efficacy?
Affinity describes how readily a compound occupies a receptor. Efficacy describes what happens once it is bound. They are independent, which is why two compounds can bind equally well and produce completely different outcomes.
What is a partial agonist?
One that produces a submaximal response even when every receptor is occupied. Adding more does not close the gap, because the ceiling belongs to the compound. In the presence of a full agonist it can behave partly like a blocker.
What is an inverse agonist?
A compound that reduces a receptor below the baseline activity it shows with nothing bound. It only makes sense for receptors with constitutive activity, meaning a fraction that adopts the active conformation spontaneously.
What does biased agonism mean?
That a compound engaging a receptor can favour one downstream route over another. Two agonists at the same target may therefore produce different patterns of activity rather than more or less of the same response.
Does calling a peptide an agonist say anything about the vial?
No. It describes what the molecule is understood to do at its target, based on published work. Whether a particular batch contains that molecule, and how pure it is, is answered by a certificate of analysis and a batch check.
References
- Stephenson, R.P. (1956). A modification of receptor theory. British Journal of Pharmacology and Chemotherapy, 11(4), 379-393.
- Black, J.W., & Leff, P. (1983). Operational models of pharmacological agonism. Proceedings of the Royal Society B, 220(1219), 141-162.
- Milligan, G. (2003). Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Molecular Pharmacology, 64(6), 1271-1276.
- Kenakin, T. (2004). Principles: receptor theory in pharmacology. Trends in Pharmacological Sciences, 25(4), 186-192.
- Kenakin, T. (2011). Functional selectivity and biased receptor signaling. The Journal of Pharmacology and Experimental Therapeutics, 336(2), 296-302.